Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Videos
Specialty Devices
Cardiovascular Devices
Return to: MDBR Home | Specialty Devices | Cardiovascular Devices

Ancora Heart raises $17.8m funding for heart failure therapy

MDBR Staff Writer Published 31 May 2018

US-based Ancora Heart has raised $17.8m financingto support continued clinical assessment of its AccuCinch ventricular repair system.

Savitr Capital and other existing investors led the initial tranche of funding in a financing round, estimated to reach $30m.

Ancora Heart will use the funding for clinical trials assessing safety and efficacy of the AccuCinch system, in addition to ongoing product development efforts.

The AccuCinch ventricular repair system is a minimally invasive investigational treatment for heart failure and functional mitral regurgitation (FMR).

The system’s procedure is aimed at directly repairing the enlarged left ventricle, targeting the  heart failure cause.

The system has been developed to reduce the size of the left ventricle, enhance left ventricular function and decrease heart failure symptoms.

Ancora Heart president and CEO Jeff Closs said: “Effectively treating heart failure and FMR is incredibly challenging today, and there are enormous unmet needs for these patients.

“This funding represents an important milestone that will advance the AccuCinch system as an alternative option that addresses the shortcomings of current heart failure and FMR treatments.”

“We have been encouraged by early clinical results and engagement from leading heart centers participating in studies of the AccuCinch system and look forward to continuing to work with them to better understand the potential benefits of our innovative technology.”

According to the company, the AccuCinch therapy holds capacity to treat heart failure and FMR patients in whom the disease has progressed beyond the ability for medications and pacemakers to manage symptoms or for whom the risks of open-heart surgery are too high.

The system will help repair the left ventricle directly to enable proper mitral valve function compared to current technologies that replicate surgical procedures to replace or repair an otherwise-normal mitral valve.